Trademark: 87729173
Word
NUGLEA
Status
Dead
Status Code
606
Status Date
Monday, January 31, 2022
Serial Number
87729173
Mark Type
4000
Filing Date
Wednesday, December 20, 2017
Published for Opposition
Tuesday, October 30, 2018
Abandoned Date
Monday, January 31, 2022

Trademark Owner History
BIOHAVEN PHARMACEUTICAL IRELAND DAC - 1st New Owner After Publication
Biohaven Pharmaceutical Holding CompanyLimited - Owner At Publication

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Trademark Events
Jan 31, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Jan 31, 2022
Abandonment - No Use Statement Filed
Jun 23, 2021
Notice Of Approval Of Extension Request E-Mailed
Jun 22, 2021
Sou Extension 5 Granted
Jun 21, 2021
Sou Extension 5 Filed
Jun 21, 2021
Sou Teas Extension Received
Dec 23, 2020
Notice Of Approval Of Extension Request E-Mailed
Dec 21, 2020
Sou Extension 4 Granted
Dec 21, 2020
Sou Extension 4 Filed
Dec 21, 2020
Sou Teas Extension Received
Aug 19, 2020
Automatic Update Of Assignment Of Ownership
Jul 1, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 30, 2020
Sou Extension 3 Granted
Jun 17, 2020
Sou Extension 3 Filed
Jun 30, 2020
Case Assigned To Intent To Use Paralegal
Jun 17, 2020
Sou Teas Extension Received
Feb 3, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 3, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 13, 2020
Withdrawal Of Attorney Granted
Jan 13, 2020
Teas Withdrawal Of Attorney Received
Dec 21, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 19, 2019
Sou Extension 2 Granted
Dec 19, 2019
Sou Extension 2 Filed
Dec 19, 2019
Sou Teas Extension Received
Oct 23, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 23, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 5, 2019
Notice Of Approval Of Extension Request E-Mailed
Jun 3, 2019
Sou Extension 1 Granted
Jun 3, 2019
Sou Extension 1 Filed
Jun 3, 2019
Sou Teas Extension Received
Dec 25, 2018
Noa E-Mailed - Sou Required From Applicant
Oct 30, 2018
Official Gazette Publication Confirmation E-Mailed
Oct 30, 2018
Published For Opposition
Oct 10, 2018
Notification Of Notice Of Publication E-Mailed
Sep 21, 2018
Assigned To Lie
Sep 6, 2018
Approved For Pub - Principal Register
Aug 31, 2018
Teas/Email Correspondence Entered
Aug 30, 2018
Correspondence Received In Law Office
Aug 30, 2018
Teas Response To Office Action Received
Mar 29, 2018
Notification Of Non-Final Action E-Mailed
Mar 29, 2018
Non-Final Action E-Mailed
Mar 29, 2018
Non-Final Action Written
Mar 27, 2018
Assigned To Examiner
Jan 8, 2018
New Application Office Supplied Data Entered
Dec 23, 2017
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24